Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
Executive Summary
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
You may also be interested in...
Sobi Targets Thrombocytopenia In $915m Swoop For Dova
The Swedish group has got hold of the ITP and CLD drug Doptelet, widening its hematology business beyond hemophilia.
$3bn Roivant Deal To Fill Holes At Dainippon
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.
Vertex Buys Semma, Gaining Cell Therapy-Based Type 1 Diabetes Treatments
Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.